Terkko Navigator / Annals of the rheumatic diseases

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study

The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series

Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)

Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) by Giollo et al

COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs

Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic dru

Rheumatic diseases in intensive care unit patients with COVID-19

Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19 by Moiseev et al

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?

Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? by Moiseev et al

Patients with lupus are not protected from COVID-19

No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit

SLE patients are not immune to covid-19: importance of sending the right message across

Response to: 'Patients with lupus are not protected from COVID-19: a comment by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit by Romao et al and 'SLE pati

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19? by Favalli et al

Correction: Knee osteoarthritis risk in non-industrial societies undergoing an energy balance transition: evidence from the indigenous Tarahumara of Mexico

Correction: High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics

Glucocorticoids: surprising new findings on their mechanisms of actions

Johann Lucas Schoenlein (1793-1864): impact without publications

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Tackling osteoarthritis during COVID-19 pandemic

Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting

Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden

In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block

Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial

Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group

Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids

Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study

SARS CoV-2 infection among patients using immunomodulatory therapies

Greetings from the editor 2021

Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India

Antirheumatic agents in covid-19: is IL-6 the right target?

COVID-19 cytokine storm: what is in a name?

The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India by Gupta et al and 'Antirheuma

Online management of rheumatoid arthritis during COVID-19 pandemic

Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: 'Online management of rheumatoid arthritis during COVID-19 pandemic by Zhang et al

The role of TASL in the pathogenesis of SLE: X marks the spot

Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? by Xie et al

Jan Mikulicz-Radecki (1850-1905): return of the surgeon